Skip to main content
SpringerLink
Log in

Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Antagonists of 5-hydroxytryptamine type 3 (5HT3) receptors reduce the nausea induced by cisplatinum, but the effects of these agents on 5HT3 receptors in the human gut remain to be defined. We examined the actions of one of these drugs (Glaxo GR 38032F) on small intestinal transit and mouth-to-cecum transit times in healthy man. We also quantified its effects on the release of peptide YY (PYY), neurotensin, human pancreatic polypeptide, gastrin-cholecystokinin, and motilin. Ten healthy volunteers were enrolled in a randomized, double-blind, placebo-controlled crossover study. Following a single intravenous dose of GR 38032F (0.15 mg/kg), we measured the time to appearance in plasma of sulfapyridine after injection of salicylazosulfapyridine into the duodenum. This was used as a measure of duodenocecal transit. The appearance of hydrogen in breath after ingestion of a meal containing lactulose was also correspondingly used to quantify the mouth-to-cecum transit of the “head” of the meal. Gastrointestinal hormones were assayed in plasma by specific RIAs; samples were drawn fasting (10 min after injection) and after breakfast (358 calories: 15.7 g protein, 55.4 g carbohydrate, 8.1 g fat). The postprandial integrated response and peak release of PYY was decreased by GR 38032F. There was also a trend for the peak release of neurotensin to be reduced. GR 38032F did not significantly alter small intestinal transit times or mouth-to-cecum transit times. We conclude that GR 38032F does not have a major effect on small intestinal transit in health.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PP, Middlemiss DN, Mylecharone EJ, Richardson BP, Saxena PR: Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576, 1986

    PubMed  Google Scholar 

  2. Richardson BP, Engel G, Donatsch P, Stadler PA: Identification of serotonin M-receptor subtypes and their specific blockage by a new class of drugs. Nature 316:126–131, 1986

    Google Scholar 

  3. Fozzard JR: Neuronal 5-HT receptors in the periphery. Neuropharmacology 23:1473–1486, 1984

    PubMed  Google Scholar 

  4. Cunningham D, Hawthorn J, Pople A, Gazet JC, Ford HT, Challoner T, Coombes RC: Prevention of emesis in patients receiving cytotoxic drugs by GR 38032F, a selective 5-HT3 receptor antagonist. Lancet 1:1461–1463, 1987

    PubMed  Google Scholar 

  5. Brittain RT, Butler A, Coates IH, Fortune BH, Hagen R, Hill JM, Humber DC, Humphrey PPA, Ireland SJ: GR 38032F, a novel selective 5HT3 receptor antagonist. Br J Pharmacol 90:87P, 1987

    Google Scholar 

  6. Leibundgut U, Lancranjan I: First results with ICS 205-930 (5HT3 receptor antagonist) in the prevention of chemotherapy-induced emesis. Lancet 1:1198, 1987

    Google Scholar 

  7. Gralla RJ, Hri M, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW: Anti-emetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909, 1981

    PubMed  Google Scholar 

  8. Gidda JS, Evans DC, Prime P, Schenck K, Cohon ML: Role of 5HT-3 receptor antagonists in gastrointestinal motility. Gastroenterology 95:867, 1988

    Google Scholar 

  9. Schuurkes JAJ, Van Nueten JM: 5-HT3 serotonergic mechanisms and stimulation of gastrointestinal motility by cis-apride. Gastroenterology 94:A414, 1988

    Google Scholar 

  10. Gullikson GW, Loeffler RF, Bianchi RG, Perkins WE, Bauer RF: Relationship of 5HT3 antagonist activity in gastrointestinal prokinetic activity in conscious dogs. Gastroenterology 95:869, 1988

    Google Scholar 

  11. Akkermans LMA, Vos A, Hoekstra A, Roelofs JMM, Horowitz M: Effect of ICS 205-930 (a specific 5HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 29:1249–1252, 1988

    PubMed  Google Scholar 

  12. Meleagros L, Kreymann B, Ghatei MA, Bloom SR: Mouth-to-cecum transit time in man is reduced by a novel serotonin M-receptor antagonist. Gut 28:A1373, 1987 (abstract)

    Google Scholar 

  13. Talley NJ, Phillips SF, Miller LJ, Haddad A: A specific 5-HT3 receptor antagonist (GR-C507/75) delays colonic transit and inhibits postprandial neurotensin (NT) release. Gastroenterology 95:891, 1988 (abstract)

    Google Scholar 

  14. Kellow JE, Borody TJ, Phillips SF, Haddad AC, Brown ML: Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit. Gastroenterology 91:396–400, 1986

    PubMed  Google Scholar 

  15. Bratton AC, Marshall EK: A new coupling component for sulfanilamide determination. J Biol Chem 128:537, 1939

    Google Scholar 

  16. Roddy DR, Koch TR, Reilly WM, Carrey JA, Go VLW: Identification and distribution of immunoreactive peptide YY in the human, canine, and murine gastrointestinal tracts: Species related antibody recognition differences. Regul Pept 18:201–212, 1987

    PubMed  Google Scholar 

  17. Chance RC, Moon NE, Johnson MG: Human pancreatic polypeptide (HPP) and bovine pancreatic polypeptide (BPP).In Methods of Hormone Radioimmunoassay, 2nd ed. BM Joffe, HR Behman (eds). New York, Academic Press, 1977, pp 657–672

    Google Scholar 

  18. Carraway R, Leeman SE: Radioimmunoassay for neurotensin, a hypothalamic peptide. J Biol Chem 251:7035–7044, 1976

    PubMed  Google Scholar 

  19. Sizemore GW, Go VLW, Kaplan EL, Sanzenbacher LJ, Holtermuller KH, Arnaud CD: Relations of calcitonin and gastrin in the Zollinger-Ellison syndrome and medullary carcinoma of the thyroid. N Engl J Med 288:641–644, 1973

    PubMed  Google Scholar 

  20. Dryburgh JR, Brown JC: Radioimmunoassay for motilin. Gastroenterology 68:1169–1176, 1975

    PubMed  Google Scholar 

  21. Lubke HJ, Warskulat C, Licht G, Frieling T, Enck P, Wienbeck M: 5HT3 receptors have minimal effects on normal gut function. Gastroenterology 94:A271, 1988 (abstract)

    Google Scholar 

  22. Korth H, Muller I, Erckenbrecht JS, Wienbeck M: Breath hydrogen as a test for gastrointestinal transit. Hepato-Gastroenterology 31:282–284, 1984

    PubMed  Google Scholar 

  23. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR: Effects of peptide YY (PYY) on mouth to a caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28:166–170, 1987

    PubMed  Google Scholar 

  24. Bond J, Levitt MD: Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med 85:546–555, 1975

    PubMed  Google Scholar 

  25. Gore S, Gilmore IT, Haigh CG, Morris AI: Specific 5-hydroxytryptamine receptor (type 3) antagonist GR 38032F slows colonie transit. Gastroenterology 96:A178, 1989 (abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Digestive Diseases Core Center, Mayo Clinic, Rochester, Minnesota

    N. J. Talley MB, BS, PhD,  S. F. Phillips MD, A. Haddad MS, L. J. Miller MD, C. Twomey MS, A. R. Zinsmeister PhD & A. Ciociola PhD

  2. Division of Gastroenterology and Digestive Diseases Core Center, Mayo Foundation, Rochester, Minnesota

    N. J. Talley MB, BS, PhD,  S. F. Phillips MD, A. Haddad MS, L. J. Miller MD, C. Twomey MS, A. R. Zinsmeister PhD & A. Ciociola PhD

Authors
  1. N. J. Talley MB, BS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. F. Phillips MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Haddad MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. J. Miller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Twomey MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. R. Zinsmeister PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Ciociola PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by grants from Glaxo Inc., USA, and from the National Institutes of Health (RR585, DK34988, and DK32121).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talley, N.J., Phillips, S.F., Haddad, A. et al. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Digest Dis Sci 34, 1511–1515 (1989). https://doi.org/10.1007/BF01537102

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01537102

Key words

Search

Navigation